Header Logo

Connection

THOMAS KOSTEN to Antipsychotic Agents

Back to Details
This is a "connection" page, showing publications THOMAS KOSTEN has written about Antipsychotic Agents.
THOMAS KOSTEN
Connection Strength
4.225
Antipsychotic Agents
  1. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. J Clin Psychiatry. 2012 Jul; 73(7):1025-33.
    View in: PubMed
    Score: 0.293
  2. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology. 2012 Apr; 62(5-6):1928-34.
    View in: PubMed
    Score: 0.283
  3. Smoking and tardive dyskinesia in male patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15; 35(7):1765-9.
    View in: PubMed
    Score: 0.273
  4. Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia. Psychopharmacology (Berl). 2009 Sep; 205(4):647-54.
    View in: PubMed
    Score: 0.237
  5. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology (Berl). 2009 May; 204(1):177-84.
    View in: PubMed
    Score: 0.230
  6. Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics. Psychopharmacology (Berl). 2008 Dec; 201(3):383-9.
    View in: PubMed
    Score: 0.224
  7. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology. 2008 Aug; 33(9):2200-5.
    View in: PubMed
    Score: 0.212
  8. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol. 2007 Jun; 27(3):246-51.
    View in: PubMed
    Score: 0.206
  9. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J Psychiatr Res. 2007 Dec; 41(12):997-1004.
    View in: PubMed
    Score: 0.198
  10. A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-na?ve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms. Neuropsychopharmacology. 2024 Apr; 49(5):893-902.
    View in: PubMed
    Score: 0.161
  11. Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Na?ve Patients with Schizophrenia: a Randomized Controlled Trial. Neurotherapeutics. 2022 04; 19(3):1037-1046.
    View in: PubMed
    Score: 0.145
  12. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000 Nov; 157(11):1835-42.
    View in: PubMed
    Score: 0.131
  13. The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia. Schizophr Res. 2019 10; 212:92-98.
    View in: PubMed
    Score: 0.120
  14. Hospital Stay in Synthetic Cannabinoid Users With Bipolar Disorder, Schizophrenia, or Other Psychotic Disorders Compared With Cannabis Users. J Stud Alcohol Drugs. 2019 03; 80(2):230-235.
    View in: PubMed
    Score: 0.116
  15. Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. Prog Neuropsychopharmacol Biol Psychiatry. 2018 07 13; 85:69-76.
    View in: PubMed
    Score: 0.109
  16. Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population. Psychopharmacology (Berl). 2014 Jan; 231(1):305-14.
    View in: PubMed
    Score: 0.079
  17. Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 01; 46:71-7.
    View in: PubMed
    Score: 0.078
  18. Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: a case-control study. J Psychiatr Res. 2013 Aug; 47(8):1049-53.
    View in: PubMed
    Score: 0.077
  19. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 01; 46:200-6.
    View in: PubMed
    Score: 0.077
  20. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol Psychiatry. 2012 Oct 15; 72(8):700-6.
    View in: PubMed
    Score: 0.073
  21. The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine. Hum Psychopharmacol. 2011 Aug; 26(6):392-6.
    View in: PubMed
    Score: 0.069
  22. Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia. Neurosci Lett. 2011 Sep 08; 502(1):37-40.
    View in: PubMed
    Score: 0.069
  23. Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics. Psychopharmacology (Berl). 2011 Jul; 216(1):9-16.
    View in: PubMed
    Score: 0.067
  24. Gender differences in the prevalence of diabetes mellitus in chronic hospitalized patients with schizophrenia on long-term antipsychotics. Psychiatry Res. 2011 Apr 30; 186(2-3):451-3.
    View in: PubMed
    Score: 0.064
  25. Smoking initiation and schizophrenia: a replication study in a Chinese Han population. Schizophr Res. 2010 Jun; 119(1-3):110-4.
    View in: PubMed
    Score: 0.063
  26. Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2010 May 30; 34(4):692-6.
    View in: PubMed
    Score: 0.063
  27. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13; 33(8):1508-12.
    View in: PubMed
    Score: 0.060
  28. Aripiprazole treatment of risperidone-induced hyperprolactinemia. J Clin Psychiatry. 2009 Jul; 70(7):1058-9.
    View in: PubMed
    Score: 0.059
  29. Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics. Neurosci Lett. 2009 Sep 22; 462(2):113-7.
    View in: PubMed
    Score: 0.059
  30. Altered interleukin-3 serum levels in drug-na?ve and neuroleptic-treated schizophrenic patients. Schizophr Res. 2008 Dec; 106(2-3):369-70.
    View in: PubMed
    Score: 0.057
  31. Elevated serum levels of tumor necrosis factor-alpha in clozapine-associated obesity in chronic schizophrenia. Schizophr Res. 2008 Dec; 106(2-3):367-8.
    View in: PubMed
    Score: 0.056
  32. Human laboratory and neuroimaging studies in substance use disorders: developing new treatment approaches. Am J Drug Alcohol Abuse. 2007; 33(6):765-7.
    View in: PubMed
    Score: 0.050
  33. Neuroleptic use in the treatment of Post-Traumatic Stress Disorder. Psychiatr Q. 2001; 72(3):197-213.
    View in: PubMed
    Score: 0.033
  34. Interaction of BDNF with cytokines in chronic schizophrenia. Brain Behav Immun. 2016 Jan; 51:169-175.
    View in: PubMed
    Score: 0.023
  35. Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia. Behav Pharmacol. 2013 Oct; 24(7):610-6.
    View in: PubMed
    Score: 0.020
  36. The interaction of polymorphisms of IL10 and DBH was associated with general symptoms of PANSS with TD in Chinese Han schizophrenic patients. PLoS One. 2013; 8(8):e70963.
    View in: PubMed
    Score: 0.020
  37. Diabetes and cognitive deficits in chronic schizophrenia: a case-control study. PLoS One. 2013; 8(6):e66299.
    View in: PubMed
    Score: 0.020
  38. Elevated interleukin-18 serum levels in chronic schizophrenia: Association with psychopathology. J Psychiatr Res. 2012 Aug; 46(8):1093-8.
    View in: PubMed
    Score: 0.018
  39. The dopamine b-hydroxylase 19 bp insertion/deletion polymorphism was associated with first-episode but not medicated chronic schizophrenia. J Psychiatr Res. 2012 Jun; 46(6):733-7.
    View in: PubMed
    Score: 0.018
  40. Sex differences in self-reported and physiological response to oral cocaine and placebo in humans. Am J Drug Alcohol Abuse. 2000 Nov; 26(4):643-57.
    View in: PubMed
    Score: 0.008
  41. Nicotine dependence and schizophrenia. Hosp Community Psychiatry. 1994 Mar; 45(3):204-6.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.